Vis enkel innførsel

dc.contributor.authorHjermstad, Marianne Jensen
dc.contributor.authorPirnat, Aleksandra
dc.contributor.authorAass, Nina Kathrine
dc.contributor.authorAndersen, Sigve
dc.contributor.authorAstrup, Guro Lindviksmoen
dc.contributor.authorDajani, Olav
dc.contributor.authorGarresori, Herish
dc.contributor.authorGuldhav, Kristin Vassbotn
dc.contributor.authorHamre, Hanne Mari
dc.contributor.authorHaukland, Ellinor Christin
dc.contributor.authorJordal, Frode
dc.contributor.authorLundeby, Tonje
dc.contributor.authorLøhre, Erik Torbjørn
dc.contributor.authorMjåland, Svein
dc.contributor.authorPaulsen, Ørnulf
dc.contributor.authorSemb, Karin
dc.contributor.authorStaff, Erik Schistad
dc.contributor.authorWester, Torunn Elin
dc.contributor.authorKaasa, Stein
dc.date.accessioned2024-10-14T11:13:10Z
dc.date.available2024-10-14T11:13:10Z
dc.date.issued2024-01-09
dc.description.abstractBackground: Effects on anticancer therapy following the integration of palliative care and oncology are rarely investigated. Thus, its potential effect is unknown.<p> <p>Aim: To investigate the effects of the complex intervention PALLiON versus usual care on end-of-life anticancer therapy.<p> <p>Design: Cluster-randomised controlled trial (RCT), registered at ClinicalTrials.gov (No. NCT01362816). The complex intervention consisted of a physician education program enhancing theoretical, clinical and communication skills, a patient-centred care pathway and patient symptom reporting prior to all consultations. Primary outcome was overall use, start and cessation of anticancer therapy in the last 3 months before death. Secondary outcomes were patient-reported outcomes. Mixed effects logistic regression models and Cox proportional hazard were used.<p> <p>Setting: A total of 12 Norwegian hospitals (03/2017–02/2021).<p> <p>Participants: Patients ⩾18 years, advanced stage solid tumour, starting last line of anticancer therapy, estimated life expectancy ⩽12 months.<p> <p>Results: A total of 616 (93%) patients were included (intervention: 309/control:307); 63% males, median age 69, 77% had gastrointestinal cancers. Median survival time from inclusion was 8 (IQR 3–14) and 7 months (IQR 3–12), and days between anticancer therapy start and death were 204 (90–378) and 168 (69–351) (intervention/control). Overall, 78 patients (13%) received anticancer therapy in the last month (intervention: 33 [11%]/control: 45 [15%]). No differences were found in patient-reported outcomes.<p> <p>Conclusion: We found no significant differences in the probability of receiving end-of-life anticancer therapy. The intervention did not have the desired effect. It was probably too general and too focussed on communication skills to exert a substantial influence on conventional clinical practice.en_US
dc.identifier.citationHjermstad MJ, Pirnat A, Aass NK, Andersen S, Astrup G, Dajani O, Garresori H, Guldhav KV, Hamre HM, Haukland ECH, Jordal F, Lundeby TL, Løhre ETL, Mjåland S, Paulsen Ø, Semb K, Staff Es, Wester TE, Kaasa S. PALLiative care in ONcology (PALLiON): A cluster-randomised trial investigating the effect of palliative care on the use of anticancer treatment at the end of life. Palliative Medicine. 2024;38(2):229-239en_US
dc.identifier.cristinIDFRIDAID 2228458
dc.identifier.doi10.1177/02692163231222391
dc.identifier.issn0269-2163
dc.identifier.issn1477-030X
dc.identifier.urihttps://hdl.handle.net/10037/35227
dc.language.isoengen_US
dc.publisherSAGE Publicationsen_US
dc.relation.journalPalliative Medicine
dc.relation.urihttps://journals.sagepub.com/doi/10.1177/02692163231222391
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2024 The Author(s)en_US
dc.rights.urihttps://creativecommons.org/licenses/by/4.0en_US
dc.rightsAttribution 4.0 International (CC BY 4.0)en_US
dc.titlePALLiative care in ONcology (PALLiON): A cluster-randomised trial investigating the effect of palliative care on the use of anticancer treatment at the end of lifeen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution 4.0 International (CC BY 4.0)
Med mindre det står noe annet, er denne innførselens lisens beskrevet som Attribution 4.0 International (CC BY 4.0)